'Study endpoints' diaporamas de présentation

936 views • 54 slides

The Science of Drug Discovery

The Science of Drug Discovery. Rich Whitley April 21, 2011. The Many Faces of Clinical Research. Natural History Study The impact of congenital cytomegalovirus infection on hearing Evaluation of a Diagnostic Assessment of an Intervention Benefits of drug eluting stent placement

573 views • 37 slides

JUPITER

JUPITER. J ustification for the U se of statins in P rimary prevention: an I ntervention T rial E valuating R osuvastatin. Rosuvastatin is not indicated for the treatment of patients with high C-Reactive Protein (CRP).

718 views • 35 slides

Michael A. Swit, Esq. Vice President

Michael A. Swit, Esq. Vice President. FDA Regulatory Issues and Ophthalmic Drug Development. Pharmaceutical Education Associates 4 th Annual Ophthalmic Drug Development & Delivery Summit September 2008 Del Mar, California. Standard Disclaimers.

405 views • 28 slides

Giuseppe De Luca, MD, PhD Aggregate Professor of Cardiology Chief Interventional Cardiology

450 views • 27 slides

Efficacy

Efficacy. Paul Meyers, MD Vice-Chairman, Dept of Pediatrics Memorial Sloan-Kettering Cancer Center. 2023.01. Osteosarcoma Survival: SEER Data. 1993-2002. 2503.01. 1.0. 0.8. 12. 12. MTP Cohort 1 (12wk). 21. 20. Historical control. 16. 11. MTP Cohort 2 (24wk). 0.6.

399 views • 21 slides

Xavier Badoux, William Wierda, Susan O'Brien, Stefan Faderl, Steven Kornblau,

A Phase II Study of Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia. Xavier Badoux, William Wierda, Susan O'Brien, Stefan Faderl, Steven Kornblau, Kimberly Yerrow, Zeev Estrov, Hagop Kantarjian, Michael Keating and Alessandra Ferrajoli.

319 views • 21 slides

Tricoci P, N Engl J Med 2012 Farb A, Circulation 2003

Safety and Tolerability of CSL112 in Patients with Stable Atherothrombotic Disease: Results from a Phase 2a, Multicenter, Randomized, Double-Blind , Placebo-Controlled , Ascending-Dose Study .

301 views • 20 slides

Bachelot T et al. Proc SABCS 2012;Abstract OT1-1-02. (Ongoing Trials Session)

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer (PERUSE). Bachelot T et al. Proc SABCS 2012;Abstract OT1-1-02. (Ongoing Trials Session). Background.

86 views • 8 slides